Related Experiment Video
Updated: Apr 28, 2026
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
Phenotype standardization for statin-induced myotoxicity
A Alfirevic1, D Neely2, J Armitage3
1Department of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Statins effectively lower lipids and reduce cardiovascular risk but can cause muscle toxicity. This study introduces a new algorithm for classifying statin-induced myotoxicity phenotypes, improving research consistency.
Area of Science:
- Pharmacology
- Clinical Toxicology
- Biomarkers
Background:
- Statins are primary lipid-lowering agents for cardiovascular disease (CVD) prevention.
- Statin-associated muscle symptoms (SAMS) range from myalgia to rhabdomyolysis.
- Lack of standardized definitions hinders research on SAMS.
Framework:
- Developed a classification system using numerical and descriptive approaches.
- Created an algorithm to define distinct statin-related myotoxicity phenotypes.
- Phenotypes include myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.
Implementation:
- Applied the algorithm to categorize patient data.
- Validated the classification system against clinical observations.
- Ensured the algorithm's applicability across diverse patient populations.
Implications:
- Standardized definitions will enhance the reliability of SAMS research.
- Improved phenotyping facilitates targeted therapeutic strategies.
- Facilitates better understanding and management of statin-induced muscle toxicity.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu